‘Global Drug Of Abuse Testing Market Worth $5.9bn In 2022’ Says Visiongain Report

15 August 2018
Pharma

Visiongain’s new report Drug of Abuse Testing Market Report 2017-2027: Employment Testing, Random Testing, Reasonable Testing, Post-Accident Testing, Saliva, Breath, Urine, Blood, Hair, Sweat, Schools and Educational Institutes, Hospitals and Healthcare Units, Government and Private Departments and Others report indicates that the global drug of abuse testing market will see $5.9bn in spending in 2022.

The global drug of abuse testing market was valued at $4.4bn in 2016 and is projected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is dominated by the Employment Testing submarket which held 39.3% share of that market in 2016.
The lead analyst of the report said: “Factors driving the growth of drug of abuse testing market is the stringent government rules and awareness regarding harmful drugs. Increase in chronic diseases caused by drug abuse has also augmented the demand for drug of abuse testing in recent years. However, the lack of availability of devices with high accuracy can be one of the restraining factors for the growth of drug of abuse testing market.”
The 165-page report contains 78 tables and 71 figures that add visual analysis in order to explain the developing trends within the global drug of abuse testing market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments by type (Employment Testing, Random Testing, Reasonable Testing, Post-Accident Testing), sample type (Saliva, Breath, Urine, Blood, Hair, Sweat) and by application (Schools and Educational Institutes, Hospitals and Healthcare Units, Government and Private Departments and Others).
The 165-page report offers market forecasts for these regional and national markets: North America (the US and Canada), Latin America (Mexico, Brazil, Argentina), Europe (Germany, France, UK, Italy, Spain, Rest of Europe), APEJ (China, India, Australia, Rest of APEJ), MEA (GCC Countries, South Africa, Rest of MEA) and Japan

Moreover, our work discusses the leading companies in the drug of abuse testing market. This report discusses the drivers, restraints as well as porter’s five forces analysis of the global drug of abuse testing market

The report Drug of Abuse Testing Market Report 2017-2027: Employment Testing, Random Testing, Reasonable Testing, Post-Accident Testing, Saliva, Breath, Urine, Blood, Hair, Sweat, Schools and Educational Institutes, Hospitals and Healthcare Units, Government and Private Departments and Others report will be of value to anyone who wants to better understand the drug of abuse testing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the drug of abuse testing market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever